{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:40:27Z","timestamp":1789612827829,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:00:00Z","timestamp":1604361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:00:00Z","timestamp":1604361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"a Grant-in-Aid for Welfare and Scientific Research","award":["19k08693"],"award-info":[{"award-number":["19k08693"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disorder caused by mutations in the polycystic kidney disease (<jats:italic>PKD<\/jats:italic>) gene. Although tolvaptan has benefits for renal involvement, the different effects depending on the gene mutation type are unknown. Thus, we explore the different effects of tolvaptan on the annual changes in total kidney volume (%TKV) and estimated glomerular filtration rate (eGFR) according to the gene mutation type in ADPKD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In total, 135 ADPKD patients were screened, and 22 patients taking tolvaptan for at least a year were retrospectively studied at the Kurume University Hospital. We examined the decline in renal function and %TKV by computed tomography and analyzed the gene mutation. Patients were classified into the following four groups according to gene mutation type:<jats:italic>PKD1<\/jats:italic>-truncated,<jats:italic>PKD1-<\/jats:italic>non-truncated,<jats:italic>PKD2<\/jats:italic>, and mutation not found. Patients were treated with tolvaptan, and the effects of tolvaptan were analyzed according to the gene mutation type.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients (age: 52.3\u2009\u00b1\u200911.2\u00a0years) were administered tolvaptan at a dose of 45 or 60\u00a0mg. No variation was observed in the annual changes in eGFR (%eGFR) (before: \u2212 10.5%\u2009\u00b1\u200913.9%, after: \u2212 14.4%\u2009\u00b1\u20098.1%,<jats:italic>P<\/jats:italic>\u2009=\u20090.139), whereas %TKV was significantly improved after the tolvaptan treatment (before: 14.9%\u2009\u00b1\u20098.0%, after: \u2212\u00a05.4%\u2009\u00b1\u20097.6%,<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Unlike %eGFR, tolvaptan treatment significantly improved %TKV, regardless of the type of gene mutation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A year treatment with tolvaptan significantly improved %TKV in patients with ADPKD, regardless of the gene mutation type.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s10157-020-01988-4","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T05:13:45Z","timestamp":1604380425000},"page":"251-260","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations"],"prefix":"10.1007","volume":"25","author":[{"given":"Tomofumi","family":"Moriyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikiko","family":"Soejima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunosuke","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanji","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakuya","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goh","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utako","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimi","family":"Takamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Hazama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Koda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Fukami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,3]]},"reference":[{"issue":"4","key":"1988_CR1","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1159\/000045214","volume":"80","author":"E Higashihara","year":"1998","unstructured":"Higashihara E, Nutahara K, Kojima M, Tamakoshi A, Yoshiyuki O, Sakai H, et al. Prevalence and renal prognosis of diagnosed autosomal dominant polycystic kidney disease in Japan. Nephron. 1998;80(4):421\u20137. https:\/\/doi.org\/10.1159\/000045214.","journal-title":"Nephron"},{"issue":"9569","key":"1988_CR2","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","volume":"369","author":"VE Torres","year":"2007","unstructured":"Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369(9569):1287\u2013301. https:\/\/doi.org\/10.1016\/S0140-6736(07)60601-1.","journal-title":"Lancet"},{"issue":"2","key":"1988_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/ng1076","volume":"33","author":"SM Nauli","year":"2003","unstructured":"Nauli SM, Alenghat FJ, Luo Y, Williams E, Vassilev P, Li X, et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet. 2003;33(2):129\u201337. https:\/\/doi.org\/10.1038\/ng1076.","journal-title":"Nat Genet"},{"issue":"25","key":"1988_CR4","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1205511.","journal-title":"N Engl J Med"},{"issue":"20","key":"1988_CR5","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377(20):1930\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1710030.","journal-title":"N Engl J Med"},{"issue":"9147","key":"1988_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/s0140-6736(98)03495-3","volume":"353","author":"N Hateboer","year":"1999","unstructured":"Hateboer N, v Dijk MA, Bogdanova N, Coto E, Saggar-Malik AK, San Millan JL, et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2 European PKD1-PKD2 Study Group. Lancet. 1999;353(9147):103\u20137. https:\/\/doi.org\/10.1016\/s0140-6736(98)03495-3.","journal-title":"Lancet"},{"issue":"6","key":"1988_CR7","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1681\/ASN.2015060648","volume":"27","author":"YH Hwang","year":"2016","unstructured":"Hwang YH, Conklin J, Chan W, Roslin NM, Liu J, He N, et al. Refining genotype-phenotype correlation in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2016;27(6):1861\u20138. https:\/\/doi.org\/10.1681\/ASN.2015060648.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"1988_CR8","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1053\/j.ajkd.2007.09.004","volume":"50","author":"E Imai","year":"2007","unstructured":"Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Tsukamoto Y, et al. Modification of the Modification of Diet in Renal Disease (MDRD) study equation for Japan. Am J Kidney Dis. 2007;50(6):927\u201337.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"1988_CR9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","volume":"145","author":"AS Levey","year":"2006","unstructured":"Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247\u201354.","journal-title":"Ann Intern Med"},{"issue":"11","key":"1988_CR10","doi-asserted-by":"publisher","first-page":"e0166288","DOI":"10.1371\/journal.pone.0166288","volume":"11","author":"M Kinoshita","year":"2016","unstructured":"Kinoshita M, Higashihara E, Kawano H, Higashiyama R, Koga D, Fukui T, et al. Technical evaluation: identification of pathogenic mutations in PKD1 and PKD2 in patients with autosomal dominant polycystic kidney disease by next-generation sequencing and use of a comprehensive new classification system. PLoS ONE. 2016;11(11):e0166288. https:\/\/doi.org\/10.1371\/journal.pone.0166288.","journal-title":"PLoS ONE"},{"issue":"6","key":"1988_CR11","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/humu.10080","volume":"19","author":"S Inoue","year":"2002","unstructured":"Inoue S, Inoue K, Utsunomiya M, Nozaki J, Yamada Y, Iwasa T, et al. Mutation analysis in PKD1 of Japanese autosomal dominant polycystic kidney disease patients. Hum Mutat. 2002;19(6):622\u20138. https:\/\/doi.org\/10.1002\/humu.10080.","journal-title":"Hum Mutat"},{"key":"1988_CR12","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/j.forsciint.2014.06.029","volume":"242","author":"M Soejima","year":"2014","unstructured":"Soejima M, Sugita Y, Koda Y. An autopsy case of subarachnoid hemorrhage due to ruptured cerebral aneurysm associated with polycystic kidney disease caused by a novel PKD1 mutation. Forensic Sci Int. 2014;242:e18\u201321. https:\/\/doi.org\/10.1016\/j.forsciint.2014.06.029.","journal-title":"Forensic Sci Int"},{"issue":"3","key":"1988_CR13","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/ndt\/gfx043","volume":"33","author":"VE Torres","year":"2018","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, et al. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transplant. 2018;33(3):477\u201389. https:\/\/doi.org\/10.1093\/ndt\/gfx043.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"1988_CR14","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.ajhg.2016.05.004","volume":"98","author":"B Porath","year":"2016","unstructured":"Porath B, Gainullin VG, Cornec-Le Gall E, Dillinger EK, Heyer CM, Hopp K, et al. Mutations in GANAB, encoding the glucosidase II\u03b1 subunit, cause autosomal-dominant polycystic kidney and liver disease. Am J Hum Genet. 2016;98(6):1193\u2013207. https:\/\/doi.org\/10.1016\/j.ajhg.2016.05.004.","journal-title":"Am J Hum Genet"},{"issue":"5","key":"1988_CR15","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.ajhg.2018.03.013","volume":"102","author":"E Cornec-Le Gall","year":"2018","unstructured":"Cornec-Le Gall E, Olson RJ, Besse W, Heyer CM, Gainullin VG, Smith JM, et al. Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease. Am J Hum Genet. 2018;102(5):832\u201344. https:\/\/doi.org\/10.1016\/j.ajhg.2018.03.013.","journal-title":"Am J Hum Genet"},{"issue":"5","key":"1988_CR16","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2215\/CJN.06300615","volume":"11","author":"VE Torres","year":"2016","unstructured":"Torres VE, Higashihara E, Devuyst O, Chapman AB, Gansevoort RT, Grantham JJ, et al. Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 Trial. Clin J Am Soc Nephrol. 2016;11(5):803\u201311. https:\/\/doi.org\/10.2215\/CJN.06300615.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"1988_CR17","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1681\/ASN.V131269","volume":"13","author":"Y Pirson","year":"2002","unstructured":"Pirson Y, Chauveau D, Torres V. Management of cerebral aneurysms in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2002;13(1):269\u201376.","journal-title":"J Am Soc Nephrol"},{"issue":"9376","key":"1988_CR18","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1016\/S0140-6736(03)13773-7","volume":"361","author":"S Rossetti","year":"2003","unstructured":"Rossetti S, Chauveau D, Kubly V, Slezak JM, Saggar-Malik AK, Pei Y, et al. Association of mutation position in polycystic kidney disease 1 (PKD1) gene and development of a vascular phenotype. Lancet. 2003;361(9376):2196\u2013201. https:\/\/doi.org\/10.1016\/S0140-6736(03)13773-7.","journal-title":"Lancet"},{"issue":"5","key":"1988_CR19","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s10157-018-1545-7","volume":"22","author":"S Makabe","year":"2018","unstructured":"Makabe S, Mochizuki T, Mitobe M, Aoyama Y, Kataoka H, Tsuchiya K, et al. Elevation of the serum liver enzyme levels during tolvaptan treatment in patients with autosomal dominant polycystic kidney disease (ADPKD). Clin Exp Nephrol. 2018;22(5):1079\u201387. https:\/\/doi.org\/10.1007\/s10157-018-1545-7.","journal-title":"Clin Exp Nephrol"},{"key":"1988_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2147\/DHPS.S142825","volume":"9","author":"S Muto","year":"2017","unstructured":"Muto S, Okada T, Yasuda M, Tsubouchi H, Nakajima K, Horie S. Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial. Drug Healthc Patient Saf. 2017;9:93\u2013104. https:\/\/doi.org\/10.2147\/DHPS.S142825.","journal-title":"Drug Healthc Patient Saf"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-020-01988-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-020-01988-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-020-01988-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T08:46:57Z","timestamp":1669452417000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-020-01988-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["1988"],"URL":"https:\/\/doi.org\/10.1007\/s10157-020-01988-4","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,3]]},"assertion":[{"value":"24 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"K. Fukami and T. Moriyama have received personal fees and research grant from Otsuka Pharmaceutical Co., Ltd. outside of the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"The study protocol was approved by the Ethical Committees of Kurume University (Approval Number: 304).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all patients included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}